<DOC>
	<DOCNO>NCT00482937</DOCNO>
	<brief_summary>The primary objective study establish safety CD-NP normal human volunteer .</brief_summary>
	<brief_title>Safety Pharmacodynamic Study CD-NP</brief_title>
	<detailed_description>The study conduct two phase . The first phase , “ ascend dose phase ” , open-label study cohort four ( 4 ) subject ( enter two subject time ) primary objective establish safety CD-NP . The second phase , “ MTD confirmation phase ” , conduct randomize , double-blind , placebo-controlled condition large cohort subject ( 10 subject ) . The primary objective phase confirm safety pharmacodynamic finding apparent MTD . Secondary objective include evaluation effect CD-NP : mean arterial pressure ( MAP ) , heart rate ( HR ) , urinary sodium potassium excretion ( UNaV UKV , respectively ) , urinary flow rate ( UV ) , creatinine clearance . Plasma concentration CD-NP , angiotensin II , aldosterone , urinary excretion rate cGMP CD-NP also determine .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Be healthy male use reliable contraception , postmenopausal female , surgically sterilize female 18 60 year age Have BMI within range 18–34 kg/m2 Be able communicate effectively study personnel Have significant disease abnormal laboratory value determine medical history , physical examination laboratory evaluation , conduct screen visit admission clinic Have normal 12lead electrocardiogram , without clinically significant abnormality Be nonsmoker define smoke past 6 month Be adequately informed nature risk study give write informed consent prior receive study medication Known hypersensitivity allergy CDNP component , nesiritide , natriuretic peptide , related compound Women pregnant breastfeed Any disease condition ( medical surgical ) , opinion investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition may interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk The presence abnormal laboratory value consider clinically significant . Positive screen Hepatitis B ( HbsAg , Hepatitis B Surface Antigen ) , Hepatitis C ( anti HCV , Hepatitis C Antibody ) , HIV ( antiHIV 1/2 ) . Received investigational drug within period 30 day prior enrollment study . Received drug therapy within 1 week , 5 halflives , prior administration first dose studyrelated treatment . This exclusion extend 4 week drug know induce inhibit hepatic drug metabolism . Use NSAIDs , sulfonamide , probenecid drug know alter renal tubular function specifically prohibit least 5 halflives prior first dose study related treatment . Consumption alcohol within 48 hour prior dose administration inpatient period . A positive urine drug screen include ethanol , cocaine , THC , barbiturates , amphetamine , benzodiazepine , opiate . A history ( within last 2 year ) alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction . A history difficulty donate blood . Donated blood blood product within 45 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Safety</keyword>
	<keyword>Heart Failure</keyword>
</DOC>